CTOs on the Move

TriNetX

www.trinetx.com

 
TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. TriNetX combines EMR data such as demographics, diagnoses, procedures, medications, labs, genomics, and deep oncology data with data derived from clinical documentation including discharge summaries, radiology reports, pathology reports, and others, to deliver the industry`s most comprehensive data set for protocol design, feasibility, site selection and patient identification.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.trinetx.com
  • 125 Cambridgepark Drive Suite 500
    Cambridge, MA USA 02140
  • Phone: 857.285.6037

Executives

Name Title Contact Details
Matthew Matturro
Senior Director, Information Security Profile
Steven Kundrot
Chief Technology Officer Profile

Funding

TriNetX raised $40M on 03/13/2019

Similar Companies

Zuni Technologies Inc

Zuni Technologies Inc is a Zuni, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Elysium Health

Elysium`s mission is to solve the biggest challenges in health with science, to help people live healthier, longer lives. Working directly with the world`s leading scientists and clinicians, Elysium translates advances in science and technology into effective, scientifically sound health products that work.

Neurogene

Neurogene is accelerating development of new genetic medicines to people with devastating neurological diseases and their families.

CoDa Therapeutics

CoDa Therapeutics, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development.